TAVR Outcomes: The Milan Experience



Two competing devices for transcatheter aortic valve replacement produced good overall outcomes in a study of 305 patients from the Milan registry, Dr. Gill Louise Buchanan and associates reported at Transcatheter Cardiovascular Therapeutics 2011.

The combined 30-day mortality for the devices – Edwards Lifesciences’ Sapien valve (ESV) and Medtronic’s CoreValve ReValving System – was 4.7%. The myocardial infarction rate was 1.3% and the rate of stroke was 1.0%, said Dr. Buchanan of the interventional cardiology unit at San Raffaele Scientific Institute in Milan, and her associates.

"There was no difference in device success (92.5% overall), combined safety end point at 30 days (61.8%) or combined efficacy end point (72.0%) at 1-year follow-up," between the two valves, but there were significant differences in conduction disturbance and/or arrhythmia occurrence and the need for pacemaker (see graph, below), the investigators said.

Note: Based on data from 305 patients treated from November 2007 to April 2011.

Source: Dr. Gill Louise Buchanan and associates

Recommended Reading

New PCI, CABG Guidelines Embrace the Heart Team
MDedge Cardiology
TAVI Treks On
MDedge Cardiology
Postsurgery Complications and Readmissions Common, Costly
MDedge Cardiology
Bypass Proves No Better Than Drugs in Preventing Stroke
MDedge Cardiology
Biodegradable Stent May Lower Late Thrombosis Risk
MDedge Cardiology